CODOX-M/IVAC-R DA-EPOCH-R in Double-hit/triple-hit Lymphoma Patients Aged 60 Years or Under

Overview

Journal Haematologica

Specialty Hematology

Date 2024 Oct 10

PMID 39385736

Authors

Suheil Albert Atallah-Yunes

Matthew J Rees

Thomas E Witzig

Thomas M Habermann

Javier Munoz

Madiha Iqbal

Ellen D McPhail

Grzegorz S Nowakowski

Affiliations

Soon will be listed here.

Abstract

Intensified chemoimmunotherapy regimens are often used in young patients with double-hit and triple-hit lymphoma (DHL/ THL) despite no survival benefit compared to R-CHOP. Favorable retrospective reports on the application of CODOX-M/IVAC-R are subject to selection bias as only young fit patients can tolerate this treatment. We conducted a retrospective analysis to investigate outcome differences between CODOX-M/IVAC-R and DA-EPOCH-R in DHL/THL patients aged 60 years or younger. One hundred and thirteen patients were identified; CODOX-M/IVAC-R (N=49) and DA-EPOCH-R (N=64). Eighty percent (39/49) achieved complete (CR) after completing CODOX-M/IVAC-R compared to 58% (37/64) with DA-EPOCH-R. The median follow-up was 5.3 years and 3.3 years for the CODOX-M/IVAC-R and DA-EPOCH-R group respectively. CODOX-M/IVAC-R demonstrated superior event-free survival (EFS) on univariate (hazard ratio [HR]=0.54, 95% confidence interval [CI]: 0.31-0.97) and multivariable analysis adjusted for age, BCL translocation (BCL2 vs. BCL6 vs. both), International Prognostic Index score and receipt of autologous stem cell transplant (adjusted HR [aHR]=0.52, 95% CI: 0.29-0.93); however there was no significant influence on OS (aHR=0.92, 95% CI: 0.46-1.84). The 1, 2 and 5 years EFS in the CODOX-M/IVAC-R group was 68.3%, 64.1% and 61.5%, respectively compared to 52.4%, 48.9% and 39.5%, respectively in the DA-EPOCH-R group. Primary refractory disease or relapse (R/R) occurred in 33% (16/49) of CODOX-M/IVAC-R and 54% (35/64) of DA-EPOCH-R recipients, and produced median OS of 10.3 months and 33.7 months, respectively, indicating poor outcomes in the CODOX-M/IVAC-R subgroup with R/R disease. More patients were able to receive subsequent salvage therapies in the DA-EPOCH-R group. No patients died of regimen toxicity and the rates of central nervous system relapse and therapy related hematologic neoplasms were similar in both groups.

References

Chapuy B, Stewart C, Dunford A, Kim J, Kamburov A, Redd R . Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018; 24(5):679-690. PMC: 6613387. DOI: 10.1038/s41591-018-0016-8. View

Alaggio R, Amador C, Anagnostopoulos I, Attygalle A, de Oliveira Araujo I, Berti E . The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36(7):1720-1748. PMC: 9214472. DOI: 10.1038/s41375-022-01620-2. View

Dodero A, Guidetti A, Tucci A, Barretta F, Novo M, Devizzi L . Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma. Leukemia. 2019; 33(4):1047-1051. PMC: 6756077. DOI: 10.1038/s41375-018-0320-9. View

Savage K, Johnson N, Ben-Neriah S, Connors J, Sehn L, Farinha P . MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009; 114(17):3533-7. DOI: 10.1182/blood-2009-05-220095. View

Petrich A, Gandhi M, Jovanovic B, Castillo J, Rajguru S, Yang D . Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014; 124(15):2354-61. DOI: 10.1182/blood-2014-05-578963. View

Oki Y, Noorani M, Lin P, Davis R, Neelapu S, Ma L . Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014; 166(6):891-901. DOI: 10.1111/bjh.12982. View

Phillips E, Burton C, Kirkwood A, Barrans S, Lawrie A, Rule S . Favourable outcomes for high-risk Burkitt lymphoma patients (IPI 3-5) treated with rituximab plus CODOX-M/IVAC: Results of a phase 2 UK NCRI trial. EJHaem. 2022; 1(1):133-141. PMC: 9176097. DOI: 10.1002/jha2.3. View

Magrath I, Adde M, Shad A, Venzon D, Seibel N, Gootenberg J . Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996; 14(3):925-34. DOI: 10.1200/JCO.1996.14.3.925. View

Dunleavy K, Fanale M, Abramson J, Noy A, Caimi P, Pittaluga S . Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Lancet Haematol. 2018; 5(12):e609-e617. PMC: 6342507. DOI: 10.1016/S2352-3026(18)30177-7. View

10.

Le Gouill S, Talmant P, Touzeau C, Moreau A, Garand R, Juge-Morineau N . The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica. 2007; 92(10):1335-42. DOI: 10.3324/haematol.11305. View

11.

Howlett C, Snedecor S, Landsburg D, Svoboda J, Chong E, Schuster S . Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis. Br J Haematol. 2015; 170(4):504-14. DOI: 10.1111/bjh.13463. View

12.

Dodero A, Guidetti A, Marino F, Tucci A, Barretta F, Re A . Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome. Haematologica. 2021; 107(5):1153-1162. PMC: 9052894. DOI: 10.3324/haematol.2021.278638. View

13.

Staton A, Cohen J . A Clinician's Approach to Double-Hit Lymphoma: Identification, Evaluation, and Management. J Oncol Pract. 2016; 12(3):232-8. DOI: 10.1200/JOP.2015.009647. View

14.

Bertrand P, Bastard C, Maingonnat C, Jardin F, Maisonneuve C, Courel M . Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas. Leukemia. 2007; 21(3):515-23. DOI: 10.1038/sj.leu.2404529. View

15.

Ye Q, Xu-Monette Z, Tzankov A, Deng L, Wang X, Manyam G . Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. Oncotarget. 2015; 7(3):2401-16. PMC: 4823044. DOI: 10.18632/oncotarget.6262. View

16.

Landsburg D, Falkiewicz M, Maly J, Blum K, Howlett C, Feldman T . Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. J Clin Oncol. 2017; 35(20):2260-2267. PMC: 6366297. DOI: 10.1200/JCO.2017.72.2157. View

17.

Sun H, Savage K, Karsan A, Slack G, Gascoyne R, Toze C . Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2015; 15(6):341-8. DOI: 10.1016/j.clml.2014.12.015. View

18.

Collinge B, Ben-Neriah S, Chong L, Boyle M, Jiang A, Miyata-Takata T . The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC. Blood. 2020; 137(16):2196-2208. DOI: 10.1182/blood.2020007193. View

19.

Nelles R, Morris K, Scott A, Kennedy G . Dose-adjusted EPOCH-R is a safe and well tolerated outpatient treatment regimen in double-hit lymphoma. Intern Med J. 2022; 53(5):773-778. DOI: 10.1111/imj.15747. View

20.

Mead G, Sydes M, Walewski J, Grigg A, Hatton C, Pescosta N . An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol. 2002; 13(8):1264-74. DOI: 10.1093/annonc/mdf253. View